Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Pathways for presenting proteins from the extracellular fluids on MHC class I molecules have been described in macrophages. However, it is uncertain whether similar mechanisms exist in dendritic cells, because conventional preparations of these cells can be contaminated with macrophages. We addressed this issue by transducing granulocyte-macrophage CSF into bone marrow cultures followed by supertransfection with myc and raf oncogenes. These immortalized clones displayed dendritic morphology, and many expressed the dendritic cell-specific markers DEC-205 and 33D1 as well as high levels of MHC molecules and costimulatory molecules. Using these cloned dendritic cells, we found that exogenous OVA could be presented on both their MHC class I and class II molecules. This presentation was markedly enhanced when the Ag was particulate and internalized by phagocytosis. Presentation of particulate OVA on MHC class I molecules was insensitive to the weak base chloroquine, but was blocked by peptide aldehyde inhibitors of the proteasome, indicating that the class I-presented peptides were generated in the cytosol. Brefeldin A, which inhibits the exocytosis of newly synthesized proteins from the endoplasmic reticulum, also inhibited Ag presentation. These results establish that dendritic cells can present exogenous Ags on MHC class I molecules and appear to use a similar phagosome to cytosol pathway as macrophages. Therefore, dendritic cells are likely to play an important role in generating immune responses to tissue transplants and tumors in vivo. Furthermore, these findings provide an approach for targeting vaccine Ags into these cells to prime immune responses in vivo.
Shen
Z
Z
Division of Lymphocyte Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Reznikoff
G
G
Dranoff
G
G
Rock
K L
KL
D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects; D000954:Antigens, Surface / Q000737:chemistry; D001854:Bone Marrow Cells; D020126:Brefeldin A; D002460:Cell Line; D002469:Cell Separation; D002738:Chloroquine / Q000494:pharmacology; D002999:Clone Cells; D003517:Cyclopentanes / Q000494:pharmacology; D003546:Cysteine Endopeptidases / Q000502:physiology; D003571:Cytochalasin B / Q000494:pharmacology; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D015395:Histocompatibility Antigens Class I / Q000187:drug effects / Q000378:metabolism*; D000949:Histocompatibility Antigens Class II / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D009097:Multienzyme Complexes / Q000502:physiology; D010047:Ovalbumin / Q000187:drug effects / Q000276:immunology; D010316:Particle Size; D010587:Phagocytosis; D046988:Proteasome Endopeptidase Complex
D000954:Antigens, Surface; D003517:Cyclopentanes; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D009097:Multienzyme Complexes; D020126:Brefeldin A; D003571:Cytochalasin B; D002738:Chloroquine; D010047:Ovalbumin; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex